The Association between PON1 (Q192R and L55M) Gene Polymorphisms and Risk of Cancer: A Meta-Analysis Based on 43 Studies
Table 1
Characteristics of qualified case-control studies included in the meta-analysis of PON1-Q192R.
Author
Year
Ethnicity
Genotyping Method
Control of source
Cancer Type
Case
Control
HWE
QQ
QR
RR
QQ
QR
RR
p
p(HWE)
Stevens et al.
2006
Caucasian
PCR-RFLP
P-B
Breast Cancer
259
182
42
238
198
47
0.38
0.54
Y
Gallicchio et al.
2007
Caucasian
PCR-RFLP
P-B
Breast Cancer
38
15
5
469
353
82
1.93
0.19
Y
Antognelli et al.
2009
Caucasian
PCR-RFLP
P-B
Breast Cancer
484
50
13
340
152
52
27.19
0.00
N
Hussein et al.
2011
Caucasian
PCR-RFLP
P-B
Breast Cancer
51
41
8
46
42
12
0.25
0.62
Y
Naidu et al.
2010
Asian
PCR-RFLP
H-B
Breast Cancer
200
158
29
115
115
22
0.81
0.37
Y
Tang et al.
2017
Asian
TaqMan
P-B
Esophagogastric
408
501
132
691
776
207
0.23
0.63
Y
Uluocak et al.
2017
Caucasian
PCR-RFLP
H-B
Prostate Cancer
24
17
8
45
42
11
0.06
0.80
Y
Wu et al.
2017
Asian
TaqMan
H-B
Breast Cancer
155
156
54
167
156
55
3.42
0.06
Y
Kaya et al.
2016
Caucasian
TaqMan
H-B
Breast Cancer
10
11
11
5
13
17
0.88
0.35
Y
Tomatir et al.
2015
Caucasian
PCR-RFLP
H-B
Hematologic Cancer
36
20
4
58
24
2
0.07
0.79
Y
Tomatir et al.
2015
Caucasian
PCR-RFLP
H-B
Hematologic Cancer
33
21
6
58
24
2
0.07
0.08
Y
Attar et al.
2015
Caucasian
PCR-RFLP
H-B
Uterine Leiomyoma
60
8
8
50
47
6
1.39
0.24
Y
Eom et al.
2015
Asian
PCR-RFLP
H-B
Lung Cancer
37
170
209
48
188
180
0.01
0.92
Y
Ahmed et al.
2015
Asian
PCR-RFLP
P-B
Colorectal Cancer
30
16
4
20
36
24
0.76
0.38
Y
Akkız et al.
2013
Caucasian
PCR-RFLP
P-B
Hepatocellular Carcinoma
109
95
13
115
88
14
0.27
0.60
Y
Vasconcelos et al.
2014
Mixed
TaqMan
H-B
Embryonal Tumors
36
85
41
104
160
72
0.51
0.48
Y
Conesa-Zamora et al.
2013
Caucasian
TaqMan
H-B
Lymphomas
83
99
33
100
104
10
7.00
0.01
N
Zhao et al.
2012
Asian
TaqMan
H-B
Glioma
161
158
52
159
167
52
0.59
0.44
Y
De Aguiar Goncalves et al.
2012
Mixed
TaqMan
H-B
Hematologic Tumor
96
102
40
74
106
54
1.790
0.180
Y
Kokouva et al.
2012
Caucasian
PCR-RFLP
H-B
Hematologic Cancer
213
88
15
181
141
29
0.04
0.83
Y
Aksoy-Sagirli et al.
2011
Caucasian
PCR-RFLP
H-B
Lung Cancer
93
111
19
121
93
20
0.13
0.72
Y
Uyar et al.
2011
Caucasian
PCR-RFLP
P-B
Renal Cell Cancer
38
21
1
27
27
6
0.04
0.84
Y
Lurie et al.
2008
Mixed
TaqMAN
P-B
Ovarian Cancer
66
120
86
122
211
111
1.07
0.30
Y
Ergen et al.
2010
Caucasian
PCR-RFLP
H-B
Osteosarcoma
27
21
2
15
33
2
0.06
0.80
Y
Martinez et al.
2010
Caucasian
TaqMan
H-B
Brain Tumor
31
33
9
22
89
109
0.37
0.54
Y
Ozturk et al.
2009
Caucasian
PCR-RFLP
H-B
Bladder Cancer
8
53
15
37
84
14
10.71
<0.001
N
Gold et al.
2009
Mixed
PCR-RFLP
P-B
Multiple Myeloma
10
19
13
9
27
19
0.01
0.91
Y
Arpaci et al.
2009
Caucasian
PCR-RFLP
H-B
Ovarian Cancer
38
6
6
17
29
6
1.46
0.23
Y
Rajaraman et al.
2008
Mixed
TaqMan
H-B
Brain Tumor
266
207
39
244
165
44
4.10
0.04
N
Searles Nielsen et al.
2005
Mixed
TaqMan
P-B
Brain Tumor
32
28
6
100
105
31
0.17
0.68
Y
Van der Logt et al.
2005
Caucasian
PCR-RFLP
P-B
Colorectal Cancer
180
150
24
158
120
17
0.87
0.35
Y
Lincz et al.
2004
Caucasian
PCR-RFLP
P-B
Multiple Myeloma
33
41
16
103
74
22
2.35
0.13
Y
Kerridge et al.
2002
Caucasian
PCR-RFLP
P-B
Lymphoma
73
50
39
103
74
22
2.35
0.13
Y
Antognelli et al.
2005
Caucasian
PCR-RFLP
H-B
Prostate Cancer
197
168
20
212
85
64
67.85
<0.001
N
Herrera et al.
2015
Mixed
TaqMan
H-B
Brain Tumor
15
32
20
12
32
14
0.64
0.42
Y
Kafadar et al.
2006
Caucasian
PCR-RFLP
H-B
Brain Tumor
43
26
15
24
18
8
1.96
0.16
Y
J. De Roos et al.
2006
Mixed
TaqMan
P-B
Hematologic Cancer
540
453
127
415
403
117
1.53
0.22
Y
Stevens et al.
2008
Mixed
TaqMan
P-B
Prostate Cancer
624
537
95
656
487
121
4.74
0.03
N
Antognelli et al.
2013
Caucasian
PCR-RFLP
H-B
Prostate Cancer
291
250
30
707
258
203
244.08
<0.001
N
Wang et al.
2012
Asian
PCR-RFLP
P-B
Lung Cancer
36
177
143
38
84
62
0.93
0.33
Y
Lee et al.
2005
Asian
TaqMan
P-B
Lung Cancer
24
80
73
11
89
77
4.999
0.025
N
Agachan et al.
2006
Caucasian
PCR-RFLP
P-B
Breast Cancer
17
4
12
6
29
17
1.461
0.230
Y
Hemati et al.
2019
Asian
PCR-RFLP
H-B
Gastric Cancer
39
41
10
62
26
2
0.03
0.87
Y
Abbreviations: PCR-RFlP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy–Weinberg equilibrium; Y, polymorphisms conforming to HWE in the control group; N, polymorphisms not conforming to HWE in the control group; H-B, hospital based; P-B, population based.